Lancet neurology
-
Randomized Controlled Trial Multicenter Study
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. ⋯ Novartis Pharma AG.
-
Randomized Controlled Trial Multicenter Study
Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial.
There is insufficient evidence to support use of occupational therapy interventions for patients with Parkinson's disease. We aimed to assess the efficacy of occupational therapy in improving daily activities of patients with Parkinson's disease. ⋯ Prinses Beatrix Spierfonds and Parkinson Vereniging.